Cargando…
COVID-19 and thrombotic microangiopathies
Severe COVID-19 can manifest as multiorgan dysfunction with pulmonary involvement being the most common and prominent. As more reports emerge in the literature, it appears that an exaggerated immune response in the form of unfettered complement activation and a cytokine storm may be a key driver of...
Autores principales: | Tiwari, Nishant R., Phatak, Sanat, Sharma, Vivek R., Agarwal, Sanjay K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055926/ https://www.ncbi.nlm.nih.gov/pubmed/33894421 http://dx.doi.org/10.1016/j.thromres.2021.04.012 |
Ejemplares similares
-
Thrombotic microangiopathy: COVID-19 or hydroxychloroquine?
por: Hasbal, Nuri Baris
Publicado: (2020) -
Thrombotic microangiopathy in a patient with COVID-19
por: Jhaveri, Kenar D., et al.
Publicado: (2020) -
No Evidence for Classic Thrombotic Microangiopathy in COVID-19
por: Falter, Tanja, et al.
Publicado: (2021) -
Thrombotic Microangiopathies
por: Radhi, Mohamed, et al.
Publicado: (2012) -
The thrombotic microangiopathies
por: Copelovitch, Lawrence, et al.
Publicado: (2008)